Wuhan Edijing Bio-Tech Co., Ltd. has secured multi-million yuan Pre-A financing to accelerate its gene editing applications and expand its market presence.

Target Company Overview

Wuhan Edijing Bio-Tech Co., Ltd. has officially announced the successful completion of a multi-million yuan Pre-A round of financing. Founded in 2019 and recognized as a national high-tech enterprise, Edijing Bio is spearheaded by an academician from the Chinese Academy of Sciences. The core team combines extensive technical expertise with strong market experience, focusing primarily on gene editing in the agricultural breeding sector.

The company has developed proprietary multi-gene editing tools and an engineering-based precise breeding platform (HiGeMP™), supported by an efficient genetic transformation system that spans multiple species. Edijing Bio has built stable partnerships with numerous scientists, breeding experts, and seed industry companies both domestically and internationally, providing long-term technical services and achieving significant results in research and industrial applications.

Industry Overview in China

The gene editing and synthetic biology industry in China has gained substantial attention and investment in recent years, driven by rapid advancements in technology and increasing demand for innovative